{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:02:41Z","timestamp":1787497361955,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22S11902300"],"award-info":[{"award-number":["22S11902300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018630","name":"Shanghai Municipal Government","doi-asserted-by":"publisher","award":["ZJ640070216"],"award-info":[{"award-number":["ZJ640070216"]}],"id":[{"id":"10.13039\/501100018630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.eclinm.2023.102372","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T02:28:55Z","timestamp":1702434535000},"page":"102372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7117-6016","authenticated-orcid":false,"given":"Yi","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davone","family":"Duangdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanthala","family":"Phamisith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Zhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Fan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Hui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Zhou","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Juan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Xiang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayfong","family":"Mayxay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102372_bib1","author":"Organization"},{"key":"10.1016\/j.eclinm.2023.102372_bib2","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib3","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib4","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2023.102372_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2023.102372_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","article-title":"Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged \u226518 years: a randomised, double-blind, phase 2b trial","volume":"23","author":"Wu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2023.102372_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41422-022-00681-3","article-title":"Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.eclinm.2023.102372_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102372_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.abn2688","article-title":"Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1\/mRNA-1273 vaccination","volume":"375","author":"Kaku","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2023.102372_bib16","series-title":"Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a phase 1\/2 trial. Infectious diseases (except HIV\/AIDS)","author":"Chen","year":"2023"},{"key":"10.1016\/j.eclinm.2023.102372_bib17","series-title":"NMPA: diagnosis and treatment of COVID-19, 9th edition","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102372_bib18","series-title":"Living guidance for clinical managment of COVID-19","author":"Organization","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102372_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104586","article-title":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and\u00a0multi-arm randomised, phase 1 trial","volume":"91","author":"Gui","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.eclinm.2023.102372_bib20","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.eclinm.2023.102372_bib21","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eclinm.2023.102372_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A\u00a0core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2023.102372_bib24","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1002\/ctm2.875","article-title":"Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS-CoV-2 vaccine","volume":"12","author":"Xu","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eclinm.2023.102372_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T\u00a0cell immunity to COVID-19 vaccines","volume":"377","author":"Wherry","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2023.102372_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104073","article-title":"Heterologous ChAdOx1\/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: the pragmatic, multi-center, three-arm, partially randomized HEVACC trial","volume":"80","author":"B\u00e1nki","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.eclinm.2023.102372_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/22221751.2022.2048969","article-title":"Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.eclinm.2023.102372_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2023.102372_bib30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib31","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2023.102372_bib33","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102372_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023005497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023005497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:56Z","timestamp":1762899956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023005497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"alternative-id":["S2589537023005497"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102372","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102372"}}